Literature DB >> 12780926

A novel indicator for surveillance colonoscopy following colorectal cancer resection.

P Skaife1, F Seow-Choen, K W Eu, C L Tang.   

Abstract

INTRODUCTION: Current surveillance for recurrent intraluminal or metachronous colorectal cancer following resection is largely undertaken by colonoscopic examination of the remaining colon. The burden on colonoscopic services is high and the procedure is expensive. Immunological faecal occult blood testing (FOBT) is a sensitive and specific test for detecting colorectal cancer, and may fine tune the need for timely surveillance colonoscopy.
METHODS: Consecutive patients due for surveillance colonoscopy following colonic resection for cancer were prospectively studied. Each patient had a single faecal sample obtained at per rectal examination on a gloved examining finger. This was subjected to immunological FOBT in the clinic, and patients were categorized as FOBT positive or negative, according to the result. Colonoscopy as well as ultrasound or CT of the liver were performed within eight weeks of FOBT.
RESULTS: Six hundred and eleven patients had both FOBT and colonoscopy. Fifty-nine (13.6%) were categorized as FOBT-positive. Of these, nine had biopsy-proven recurrent or metachronous cancer, 12 patients had one, or more adenomatous polyps, one patient had radiation proctitis and two patients had pan-colonic mucositis following chemotherapy. In the remaining 552 FOBT-negative patients, no cancers were found. Thirty-eight patients had polyps that were removed. The sensitivity and specificity for detecting cancer by immunological FOBT was 100% sensitivity for detecting adenomatous polyps was 24% but specificity was 93%.
CONCLUSION: The immunological faecal occult blood test provides sensitive detection of metachronous and recurrent cancer in postoperative surveillance. Routine application may be used to reduce the frequency of colonoscopic surveillance, as a negative FOBT may be taken as a sign that colonoscopy may be deferred safely.

Entities:  

Mesh:

Year:  2003        PMID: 12780926     DOI: 10.1046/j.1463-1318.2003.00379.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  4 in total

1.  Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.

Authors:  P A Bampton; J J Sandford; S R Cole; A Smith; J Morcom; B Cadd; G P Young
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Charles J Kahi; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas J Robertson; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-02-12       Impact factor: 10.864

3.  Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study.

Authors:  Jochim S Terhaar sive Droste; Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Vincent A Steeman; Usha Coblijn; Lisette van der Eem; Ruud Duijkers; Anneke A Bouman; Gerrit A Meijer; Annekatrien C T M Depla; Pieter Scholten; Ruud J L F Loffeld; Veerle M H Coupé; Chris J J Mulder
Journal:  BMC Gastroenterol       Date:  2012-07-24       Impact factor: 3.067

4.  General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial.

Authors:  D A Wattchow; D P Weller; A Esterman; L S Pilotto; K McGorm; Z Hammett; C Platell; C Silagy
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.